Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04382846 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Novel Regimens in COVID-19 Treatment

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 80 to 160 · Study sites: 0 to 2 · Interventions: Azithromycin (Drug), Chloroquine (Drug), Ivermectin (Drug), Nitazoxanide (Drug) to Nitazoxanide (Drug) · 2 morev2 Show 5 more changesShow less
    • Enrollment target: 80 to 160
    • Study sites: 0 to 2
    • Interventions: Azithromycin (Drug), Chloroquine (Drug), Ivermectin (Drug), Nitazoxanide (Drug) to Nitazoxanide (Drug)
    • Study description revised
    • Study arms: 4 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Trial Details
NCT Number NCT04382846
Lead Sponsor Tanta University
Conditions COVID, Corona Virus Infection
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov